BioNTech’s COVID-19 vaccine transformed it from an oncology-focused biotech into a household name. Now, as demand for its Pfizer-partnered shot Comirnaty falls, the company is pivoting back to its early mission: turning its cancer pipeline into a sustainable business.
Pfizer booked $37.8 billion in worldwide Comirnaty revenue in 2022. But sales have since plummeted.
The challenge of driving growth has since been exacerbated by recent political attacks on mRNA technology and vaccines in the U.S. under the tenure of HHS Secretary Robert F. Kennedy Jr.
BioNTech posted a net loss of about $1.56 billion in the first six months of 2026. In early May, it announced plans to exit several manufacturing sites in Germany and Singapore, affecting up to 1,860 jobs.
On top of that, the company is preparing to lose its co-founders, CEO Ugur Sahin and Chief Medical Officer Özlem Türeci, who plan to leave their posts by the end of 2026 to establish an independent biotech focused on next-generation mRNA technology.
Now, a new leader is set to steer BioNTech into its next era.
Guido Oelkers will take over as CEO by Feb. 1, 2027 at the latest BioNTech announced this month. Oelkers is grabbing the reins of a company in a strong financial position despite its recent losses, with a war chest including about $19.2 billion in cash, cash equivalents and security investments as of June 30.
His mandate is to turn that capital into multiple approved products by 2030 and build the global commercial organization needed to support them — all while managing declining sales of BioNTech’s sole marketed product.
BioNTech’s board highlighted Oelkers’ experience building drug portfolios and scaling global organizations. Since taking over Sobi in 2017, he has more than quadrupled the Swedish biopharma’s revenue. His appointment also bears out a prediction biotech consultant Stella Vnook made to PharmaVoice in May: BioNTech’s strategic pivot would likely require an outsider with a fresh perspective.
BioNTech said it will continue on its current course until Oelkers arrives, although he may make adjustments after reviewing the business.
“As with any leader, Guido Oelkers may refine priorities to empower execution,” a BioNTech spokesperson said in an email. “He will share his detailed vision and strategic framework to accelerate the company’s evolution once he has had the opportunity to familiarize himself with the company and our strengths.”
Transforming oncology R&D into new growth
BioNTech spent about $2.4 billion on R&D in 2025 and now has more than 25 phase 2 and 3 oncology trials.
Although the company remains active in the infectious disease space, its late-stage oncology pipeline now spans immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies.
The centerpiece of the pipeline is pumitamig, an investigational bispecific immunomodulator targeting PD-L1 and VEGF-A. BioNTech gained the asset through its $800 million acquisition of China-based Biotheus, a deal announced in 2024 and completed in 2025, and is now jointly developing it with Bristol Myers Squibb. Pumitamig is being evaluated in seven pivotal trials spanning small and non-small cell lung cancers, triple-negative breast cancer, colorectal cancer and gastric cancer, alongside earlier-stage studies in other tumors.
The company released interim results from a global phase 2 trial for untreated patients with extensive-stage small cell lung cancer last year. Those results showed a confirmed response rate of 76.3% and a disease control rate of 100% among 38 efficacy-evaluable patients. If that performance holds in phase 3, the drug could mark a new standard of care for some patients, according to the company.
The company is also in phase 2 with a personalized mRNA cancer immunotherapy autogene cevumeran it’s developing with Genentech for pancreatic and colorectal cancer.
And its phase 3 anti-CTLA-4 antibody candidate has gained momentum in the clinic. In the non-pivotal first stage of a two-part phase 3 trial in previously treated metastatic squamous non-small cell lung cancer, 63.1% of patients receiving gotistobart were alive at 12 months, compared with 30.3% who were treated with standard chemotherapy.
Going forward, the central challenge for BioNTech will be converting its R&D capital into approvals before the economics of the pandemic era fade further. And with Türeci leaving, the search is on for a new chief medical officer with extensive late-stage clinical development experience to help complete its transition from a COVID-vaccine biotech into a diversified oncology company.
BioNTech’s outgoing CEO acknowledged that the leadership changes, including the installation of a new chief, will be crucial to that evolution.
“This transition reflects the natural evolution of BioNTech from a pioneering research organization into a global biopharmaceutical company with multiple commercial products,” Sahin said in BioNTech’s most recent earnings call. “The next phase of this evolution requires the corresponding leadership skills, and I am confident we have found this in [Oelkers].
